Story perspectives
FDA Approves Novavax COVID Vaccine Amid Heart Risk Concerns
5/20/2025
49 4
1 of 1
Story summary
- The FDA has granted approval for Novavax's COVID-19 vaccine, targeting adults aged 65 and older, as well as those aged 12-64 with health conditions. This decision comes amid skepticism from Health Secretary Robert F. Kennedy Jr., sparking concerns about equitable public health access. Novavax is also required to investigate potential heart risks linked to the vaccine.
